Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $22 to $20.
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $22 to $20.